Christina Claus

This inventor holds 14 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ag. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christina Claus. Retrieved from https://idiyas.com/inventor/christina-claus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 10 (Patent Applications = 23)

Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 115(Granted Patents)

Location History:

Schlieren, CH (2020 - 2022)
Ennetbaden, CH (2019 - 2024)

Company Filing History:

13 out of 5,027

Hoffmann-La Roche Inc.

patents

1 out of 181

F. Hoffmann-La Roche Ag

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

4-1BB Agonists

Bispecific Antibodies

Tumor Necrosis Factor

Antigen Binding Molecules

Cancer Treatment

OX40 Specific Antibodies

Targeted Therapy

Trimeric Ligands

HER2 Targeting

Cell Based Assays

Polynucleotides

Tenascin Binding Moiety

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12565530 - COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS/ANTI-FAP BINDING DOMAIN AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODY (2026-03-03),

2. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

3. 12281153 - Combination therapy with targeted 4-1BB (CD137) agonists (2025-04-21),

4. 12240911 - Bispecific antibodies specific for OX40 (2025-03-04),

5. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

6. 12065478 - HER2-targeting antigen binding molecules comprising 4-1BBL (2024-08-20),

7. 11536716 - Cell based assay for determining antibody or ligand binding and function (2022-12-27),

8. 11447558 - Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9 (2022-09-20),

9. 11306154 - Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer (2022-04-19),

10. 11267903 - Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer (2022-03-08),

11. 11149083 - Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety (2021-10-19),

12. 10526413 - Bispecific antibodies specific for OX40 (2020-01-07),

13. 10464981 - Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules (2019-11-05),

14. 10392445 - Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2019-08-27),

Title: The Innovative Contributions of Inventor Christina Claus

Introduction

Christina Claus is a remarkable inventor based in Ennetbaden, Switzerland, known for her significant contributions to the field of biomedical innovation. With an impressive portfolio of 12 patents, Claus has made strides in developing therapies that target critical cancer receptors, showcasing the intersection of medicine and cutting-edge science.

Latest Patents

Among her latest patents, Christina's invention titled "Combination therapy with targeted 4-1BB (CD137) agonists" focuses on employing these agonists in various combination therapies, especially in conjunction with HER-2 targeting agents. This innovation aims to improve cancer treatment outcomes by enhancing the efficacy of existing therapies. Moreover, her patent for "Bispecific antibodies specific for OX40" introduces novel bispecific antigen-binding molecules designed to interact with target cell antigens and members of the TNF receptor family. This invention not only emphasizes her prowess in antibody design but also opens avenues for advanced therapeutic strategies in oncology.

Career Highlights

Currently, Christina Claus is an integral part of Hoffmann-La Roche Inc., where she plays a pivotal role in the development of innovative therapeutic solutions. Her career is marked by a dedication to advancing cancer treatment methodologies through her innovative research and patent contributions. Her work has been instrumental in positioning her as a leading figure in her field.

Collaborations

Throughout her career, Christina has collaborated with numerous esteemed professionals, including colleagues Claudia Ferrara Koller and Christian Klein. These collaborations have further enriched her research, fostering an environment of shared knowledge and innovation that is essential for breakthroughs in biomedical applications.

Conclusion

Christina Claus exemplifies the spirit of innovation and dedication to improving cancer treatment through her inventive mind and collaborative efforts. Her patented technologies and contributions to biomedical research mark her as a significant inventor whose work continues to resonate within the scientific community, ultimately enhancing patient care and treatment outcomes in oncology.

Profile summary based on public USPTO records.